Market capitalization | $17.07m |
Enterprise Value | $-32.19m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.44 |
EV/Sales (TTM) EV/Sales | -19.16 |
P/S ratio (TTM) P/S ratio | 10.16 |
P/B ratio (TTM) P/B ratio | 0.22 |
Sales growth (TTM) Sales growth | 28.74% |
Turnover (TTM) Turnover | $1.68m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
5 Analysts have issued a Lyra Therapeutics Inc forecast:
5 Analysts have issued a Lyra Therapeutics Inc forecast:
Dec '23 | |
Current assets | 105 105 |
Fixed assets | 38 38 |
Total assets | 143 143 |
Dec '23 | |
Equity | 89 89 |
Debt capital | 53 53 |
Total capital | 143 143 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Head office | United States |
CEO | Maria Palasis |
Employees | 88 |
Founded | 2005 |
Website | www.lyratherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.